NeutriSci International (TSX-V: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9) Announces a Major R&D MOU with Scientus Pharma to Develop a Medical Cannabinoid Retail Product

NeutriSci International (TSX-V: NU) (OTCQB: NRXCF) (FRA: 1N9) this morning announced that it has entered into a major research and development (R&D) Memorandum of Understanding (“MOU”) with Scientus Pharma Inc. In accordance of the terms set forth in the MOU, the two companies have agreed to share their technologies to develop, test, produce, and distribute a medical cannabinoid product for current retail distribution networks throughout Canada. “This Scientus Pharma partnership helps position us at the forefront of developing new and innovative cannabinoid based medical products in Canada. Scientus Pharma, along with its existing partnerships, is sure to be a dominant player in the cannabis space in Canada. Through a collaborative effort, we will incorporate NeutriSci’s IP, technology and ingredients with Scientus’ expertise, proprietary technical know-how, and resources. By leveraging both parties existing partnerships, we will be positioned to offer the national retail consumer a safe, effective, dose controlled product that completes our ‘plant to blood stream’ strategy,” NeutriSci president Glen Rehman stated in the news release.